InvestSMART

SomnoMed Limited (ASX:SOM)

ALERT: Price-sensitive ASX Announcement for SOM
Current share price for SOM : $0.490 -0.17 (-25.76%)+
Announcement
Release
27 Feb 2026 8:13AM
Price at Release
$0.660
Full Release
download
Summary
SomnoMed Limited's investor presentation for the first half of fiscal year 2026 highlights significant growth and strategic initiatives. The company reported a 13% increase in revenue, reaching $60.7 million, and a 35% rise in EBITDA to $7.8 million, with improved profit margins. They continue to lead the market in oral appliance therapy for sleep apnea and have expanded their manufacturing capacity. SomnoMed is advancing the commercialization of Rest Assure®, a compliance-monitored oral device, while strengthening its leadership team. The company is pursuing sustainable growth with plans for further investment and innovation, projecting substantial revenues and EBITDA growth for FY26.
Key Points
  • SomnoMed Limited reported a 13% increase in revenue for the first half of the fiscal year 2026, totaling $60.7 million.
  • The company's EBITDA increased by 35% year-on-year, reaching $7.8 million, with an improved margin of 13%.
  • SomnoMed is the global leader in oral appliance therapy for sleep apnea and is focusing on the expansion of its manufacturing capabilities.
  • The company has developed Rest Assure®, an FDA-cleared oral device with built-in compliance monitoring, and is exploring options for accelerated commercialization.
  • SomnoMed aims for sustainable growth and innovation, with plans for further investment in manufacturing site expansion and the development of new products.
  • The company reported positive operating cash flow before and after leases of $4.1 million and $2.5 million respectively.
  • SomnoMed has strengthened its leadership team with key appointments to support its growth strategy.
  • The company is forecasting FY26 revenue between $119 million and $126 million and EBITDA between $10 million and $12 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.